---
schema_version: "secwatch.filing_event.v1"
accession: "0000947871-26-000310"
form_type: "8-K"
ticker: "EMBC"
cik: "0001872789"
company_name: "Embecta Corp."
filed_at: "2026-03-20T23:59:59+00:00"
generated_at: "2026-05-15T09:31:01.558579+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Embecta to acquire Owen Mumford for up to £150M; adds drug-delivery platform

## Summary
- Upfront cash payment of £100M at closing; up to £50M earnout based on Aidaptus net sales by end of 2028.
- Owen Mumford generated £69.4M revenue in FY2025; transaction expected to close in Embecta's fiscal Q3 2026.
- Deal unanimously approved by Embecta board; expected to be accretive to adjusted net income after FY2028.
- Acquisition positions Embecta in drug-delivery devices for chronic care (obesity, diabetes, autoimmune, anaphylaxis).
- Embecta plans to fund upfront with borrowings under its revolving credit facility.

## SEC filing metadata
- accession: 0000947871-26-000310
- form_type: 8-K
- ticker: EMBC
- cik: 0001872789
- company_name: Embecta Corp.
- filed_at: 2026-03-20T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1872789/000094787126000310/0000947871-26-000310-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1872789/000094787126000310/ss6090062_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000947871-26-000310
- JSON: https://secwatch.observer/filing/0000947871-26-000310.json
- Plain text: https://secwatch.observer/filing/0000947871-26-000310.txt

## Key facts
- Material Agreements
  Embecta Corp. entered into a asset purchase with Owen Mumford Holdings Limited valued at up to £150 million (effective 2026-03-19).
  - Action: entry
  - Agreement: asset purchase
  - Counterparty: Owen Mumford Holdings Limited
  - Value: up to £150 million
  - Effective: 2026-03-19
  source text: hat it has entered into a definitive agreement to acquire Owen Mumford Holdings Limited (“Owen Mumford”), a privately held, UK-based innovator and manufacturer of medical devices and drug-delivery technologies, in a transaction valued at up to £150 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1872789/000094787126000310/0000947871-26-000310-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.